RECURRENT HEAD AND NECK CANCER
Clinical trials for RECURRENT HEAD AND NECK CANCER explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HEAD AND NECK CANCER trials appear
Sign up with your email to follow new studies for RECURRENT HEAD AND NECK CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo aims to boost immune System's fight against tough cancer
Disease control OngoingThis study is testing if adding a drug called ramucirumab to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for people with advanced head and neck cancer that has returned or spread. The goal is to see if the combination helps shrink tumors and control…
Matched conditions: RECURRENT HEAD AND NECK CANCER
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
New cancer vaccine combo aims to outperform standard treatment in major trial
Disease control OngoingThis large, late-stage trial is testing whether adding an experimental immunotherapy called PDS0101 to the standard drug pembrolizumab (Keytruda) helps people with advanced HPV-positive head and neck cancer live longer. The study will enroll about 351 adults whose cancer has retu…
Matched conditions: RECURRENT HEAD AND NECK CANCER
Phase: PHASE3 • Sponsor: PDS Biotechnology Corp. • Aim: Disease control
Last updated Mar 10, 2026 12:53 UTC